apceth entered Letter of Intent with Australian Company

apceth, the global innovator and leader in engineered mesenchymal stem cell (MSC) technology and MSC-based gene therapies, has entered a letter of intent with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd for the testing and use of Cynata’s proprietary Cymerus™ technology.

Download Press Release by Cynata (PDF)